Biomarker Disease Diagnosis Targeted by Thermo Fisher Scientific and Immunodiagnostik Collaboration - - Chromatography Online
Biomarker Disease Diagnosis Targeted by Thermo Fisher Scientific and Immunodiagnostik Collaboration

LCGC Europe eNews

Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis.

The collaboration seeks to further biomarker research, by combining the antibody-based detection technology developed by Immunodiagnostik with the liquid–chromatrography tandem mass spectrometry (LC–MS–MS) analytical technology from Thermo Scientific. The companies hope to enable the development of assays specifically for the diagnosis of cardiovascular disease and bone metabolism disorders. Furthermore, Immunodiagnostik will utilize its academic and clinical network connections to allow the validation of developed assays.

“We are impressed with Immundiagnostik’s antibody expertise, and are confident that the immunoaffinity-purification of proteins will take quantitative LC–MS–MS protein analysis to the next level,” said Jeff Zonderman, Thermo Fisher director of clinical and toxicology LC–MS.

For more information please visit: www.thermofisher.com

ADVERTISEMENT

LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 
Survey
CHROMacademy
Are you aware of CHROMacademy and the learning tools it offers?
Yes, I would like to know more
Yes, I am not interested
No, I would like to know more
No, I am not interested
Yes, I would like to know more
69%
Yes, I am not interested
10%
No, I would like to know more
15%
No, I am not interested
6%
View Results

LCGC COLUMNISTS 2014

Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: Avoiding Reversed-Phase Chromatography Problems Through Informed Method Development Practices: Choosing the Stationary-Phase Chemistry


Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: Seven Common Faux Pas in Modern HPLC


MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: Estimating Resolution for Marginally Separated Peaks


More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: LCGC Europe eNews,
Click here